123 related articles for article (PubMed ID: 9837768)
1. Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation.
Wimmer K; Vinatzer U; Zwirn P; Fonatsch C; Wieser R
Biochem Biophys Res Commun; 1998 Nov; 252(3):691-6. PubMed ID: 9837768
[TBL] [Abstract][Full Text] [Related]
2. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
[TBL] [Abstract][Full Text] [Related]
3. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
[TBL] [Abstract][Full Text] [Related]
4. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
5. Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3.
Khanna-Gupta A; Lopingco MC; Savinelli T; Zibello T; Berliner N; Perkins AS
Oncogene; 1996 Feb; 12(3):563-9. PubMed ID: 8637713
[TBL] [Abstract][Full Text] [Related]
6. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
7. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
8. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
[TBL] [Abstract][Full Text] [Related]
9. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
10. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
Sitailo S; Sood R; Barton K; Nucifora G
Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
[TBL] [Abstract][Full Text] [Related]
11. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
12. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
13. [Study on expression of Evi1 and MDS1-Evi1 genes in myelodysplastic syndromes].
Xu K; Wang L; Hao Y
Zhonghua Xue Ye Xue Za Zhi; 1998 Jun; 19(6):315-9. PubMed ID: 11243114
[TBL] [Abstract][Full Text] [Related]
14. The role of EVI1 in normal and leukemic cells.
Buonamici S; Chakraborty S; Senyuk V; Nucifora G
Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
[TBL] [Abstract][Full Text] [Related]
15. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract][Full Text] [Related]
16. EVI1 and hematopoietic disorders: history and perspectives.
Nucifora G; Laricchia-Robbio L; Senyuk V
Gene; 2006 Mar; 368():1-11. PubMed ID: 16314052
[TBL] [Abstract][Full Text] [Related]
17. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
[TBL] [Abstract][Full Text] [Related]
18. EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages.
Steinleitner K; Rampetsreiter P; Köffel R; Ramanathan G; Mannhalter C; Strobl H; Wieser R
Anticancer Res; 2012 Nov; 32(11):4883-9. PubMed ID: 23155256
[TBL] [Abstract][Full Text] [Related]
19. Ecotropic viral integration site-1 is activated during, and is sufficient for, neuroectodermal P19 cell differentiation.
Kazama H; Kodera T; Shimizu S; Mizoguchi H; Morishita K
Cell Growth Differ; 1999 Aug; 10(8):565-73. PubMed ID: 10470856
[TBL] [Abstract][Full Text] [Related]
20. EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation.
Shimizu S; Nagasawa T; Katoh O; Komatsu N; Yokota J; Morishita K
Biochem Biophys Res Commun; 2002 Apr; 292(3):609-16. PubMed ID: 11922610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
